RARA CRAFT DATABASE for FDA Medical Devices
510(k)K181662

FDA DEVICE FACTS

Iridex TruFocus LIO Premiere

Iridex Corporation

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 5, 2018PRODUCT CODEGEX

Indications for use

The Iridex TruFocus LIO Premiere Laser Indirect Ophthalmoscope with the Family of Iridex® IQ Laser Systems (IQ 532 [532nm], IQ 577 [577nm], IQ 630-670 [630nm-670nm], IQ 810 [810nm]), hand pieces, delivery devices & accessories that are used with them to deliver laser energy in either CW-pulse, MicroPulse™ or LongPulse™ mode. Intended for soft and fibrous tissue, including osseous tissue incision, excision, coagulation, vaporization, ablation and vessel hemostasis in the medical specialties of, dermatology, ear, nose and throat (ENT)/ otolaryngology, and ophthalmology as follows: 532 nm: Dermatology:

• Pigmented Skin Lesions

• Vascular Lesions Ear, Nose, and Throat (ENT)/ Otolaryngology Otosclerotic Hearing loss and/or diseases of the inner ear:

• Stapedectomy

• Stapedotomy

• Myringotomies

• Lysis of Adhesions

• Control of Bleeding

• Removal of Acoustic Neuromas

• Soft tissue Adhesion in Micro/Macro Otologic Procedures Ophthalmology: Indicated for retinal photocoagulation, laser trabeculoplasty, iridotomy, iridoplasty including:

• Retinal photocoagulation (RPC) for the treatment of

- Diabetic retinopathy, including:

- Nonproliferative retinopathy

- Macular edema

- Proliferative retinopathy

• Retinal tears and detachments

- Lattice degeneration

- Age-related macular degeneration (AMD)

- Retinopathy of prematurity

- Sub-retinal (choroidal) neovascularization

- Central and branch retinal vein occlusion

• Laser trabeculoplasty, iridotomy, iridoplasty for the treatment of glaucoma, including

- Primary open angle/Closed angle 577nm Dermatology:

• Treatment of Vascular and pigmented lesions Ophthalmology: Indicated for use in photocoagulation of both anterior and posterior segments including:

• Retinal photocoagulation, panretinal photocoagulation and intravitreal endophotocoagulation of vascular and structural abnormalities of the retina and choroid including :

- Proliferative and nonproliferative diabetic retinopathy;

- Choroidal neovascularization;

- Branch retinal vein occlusion;

- Age-related macular degeneration

- Retinal tears and detachments

- Retinopathy of prematurity

• Iridotomy, iridectomy and trabeculoplasty in angle closure glaucoma and open angle glaucoma 630 - 670nm Ophthalmology: Indicated for use in photocoagulation of both anterior and posterior segments including:

• Retinal photocoagulation, panretinal photocoagulation and intravitreal endophotocoagulation of vascular and structural abnormalities of the retina and choroid including:

- Proliferative and non-proliferative diabetic retinopathy;

- Choroidal neovascularization;

- Branch retinal vein occlusion;

- Age-related macular degeneration

- Retinal tears and detachments

- Retinopathy of prematurity

• Iridotomy, iridectomy and trabeculoplasty in angle glaucoma and open angle glaucoma 810nm Ophthalmology: Indicated for retinal photocoagulation, laser trabeculoplasty, transscleral cyclophotocoagulation, transscleral retinal photocoagulation, iridotomy, including the following examples:

• Retinal photocoagulation for the treatment of:

• Diabetic retinopathy, including:

- Nonproliferative retinopathy

- Macular edema

- Proliferative retinopathy

• Retinal Tears, Detachments and Holes

• Lattice degeneration

• Age-related macular degeneration (AMD) with choroidal neovascularization (CNV)

• Retinopathy of prematurity

• Sub-retinal (choroidal) neovascularization

• Central and Branch Retinal Vein Occlusion

• Laser trabeculoplasty, Iridotomy, Transscleral Cyclophotocoagulation (TSCPC) for the treatment of glaucoma, including:

- Primary open angle

- Closed angle

- Refractory Glaucoma (recalcitrant/uncontrolled)

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 26, 2026